COPD with FEV1 <50% and Non-Eosinophilic Phenotype: What Is the First-Line Treatment?
Not all COPD patients are managed the same way. Those classified as high risk — based on lung function, symptom burden, or exacerbation history — require a different therapeutic strategy, which is further refined by their inflammatory phenotype.
Clinical Scenario
This protocol applies to patients with COPD meeting the high-risk threshold: FEV1 <50% predicted, and/or dyspnoea mMRC ≥ 2, and/or two or more exacerbations in the previous year, or at least one exacerbation requiring hospitalisation. These patients also have a non-eosinophilic inflammatory profile, with blood eosinophils below 300 cells/µL.
Treatment Approach
For this specific phenotype — high risk and non-eosinophilic — first-line management is built around a dual bronchodilator strategy. The complete regimen, agent selection, and clinical algorithm are available in the structured protocol below.
References
DOI: 10.3390/jcm13020303
If any of these requirements are exceeded, they will be classified as "high risk".
On the other hand, patients at high risk should be differentiated by phenotype: in the case of a non-acute and non-eosinophilic patient, treatment should be initiated with LABA + LAMA, and in the case of an eosinophilic patient, treatment should be initiated with IC + LABA (Figure 1).
In patients with permanent symptoms, it recommends starting directly with dual LAB.
View source ↗